195 related articles for article (PubMed ID: 38349553)
1. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.
Chen A; Yu Z; Ma N; Lu X; Zhang Y; Xu W; Wang Y; Xie J; Qin Y; Mo G; Wu S; Hou J; Zhu W
Cancer Immunol Immunother; 2024 Feb; 73(3):49. PubMed ID: 38349553
[TBL] [Abstract][Full Text] [Related]
2. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.
Hussein MS; Li Q; Mao R; Peng Y; He Y
Front Immunol; 2023; 14():1114770. PubMed ID: 37215108
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract][Full Text] [Related]
4. Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment.
Wang S; Zhou X; Zeng Z; Sui M; Chen L; Feng C; Huang C; Yang Q; Ji M; Hou P
J Nanobiotechnology; 2021 Oct; 19(1):302. PubMed ID: 34600560
[TBL] [Abstract][Full Text] [Related]
5. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC.
Chen Y; Shang H; Wang C; Zeng J; Zhang S; Wu B; Cheng W
Int J Nanomedicine; 2022; 17():105-123. PubMed ID: 35027829
[TBL] [Abstract][Full Text] [Related]
6. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
7. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.
Zhu W; Zhang Z; Chen J; Chen X; Huang L; Zhang X; Huang X; Ma N; Xu W; Yi X; Lu X; Fu X; Li S; Mo G; Wang Y; Yuan G; Zang M; Li Q; Jiang X; He Y; Wu S; He Y; Li Y; Hou J
Signal Transduct Target Ther; 2024 Apr; 9(1):101. PubMed ID: 38643203
[TBL] [Abstract][Full Text] [Related]
8. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
[TBL] [Abstract][Full Text] [Related]
9. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
11. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
[TBL] [Abstract][Full Text] [Related]
12. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer.
Zhou TJ; Zhang MM; Liu DM; Huang LL; Yu HQ; Wang Y; Xing L; Jiang HL
Biomaterials; 2024 Mar; 305():122447. PubMed ID: 38154441
[TBL] [Abstract][Full Text] [Related]
13. Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors.
Xu Q; Zhan G; Zhang Z; Yong T; Yang X; Gan L
Theranostics; 2021; 11(4):1937-1952. PubMed ID: 33408790
[TBL] [Abstract][Full Text] [Related]
14. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma.
Liu J; Li X; Chen J; Zhang X; Guo J; Gu J; Mei C; Xiao Y; Peng C; Liu J; Hu X; Zhang K; Li D; Zhou B
ACS Appl Mater Interfaces; 2023 Feb; 15(5):6260-6273. PubMed ID: 36695492
[TBL] [Abstract][Full Text] [Related]
15. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
[TBL] [Abstract][Full Text] [Related]
17. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
[TBL] [Abstract][Full Text] [Related]
18. Fe-MnO
Huang D; Xu D; Chen W; Wu R; Wen Y; Liu A; Lin L; Lin X; Wang X
Biomed Pharmacother; 2023 May; 161():114431. PubMed ID: 36827713
[TBL] [Abstract][Full Text] [Related]
19. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
20. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
